- Home
- MYND vs NRXP Comparison
MYND vs NRXP Comparison
Compare MYND & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYND
- NRXP
- Stock Information
- Founded
- MYND 1998
- NRXP 2015
- Country
- MYND United States
- NRXP United States
- Employees
- MYND N/A
- NRXP N/A
- Industry
- MYND Other Consumer Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- MYND Real Estate
- NRXP Health Care
- Exchange
- MYND Nasdaq
- NRXP Nasdaq
- Market Cap
- MYND 38.8M
- NRXP 32.6M
- IPO Year
- MYND 2017
- NRXP N/A
- Fundamental
- Price
- MYND $0.72
- NRXP $2.01
- Analyst Decision
- MYND
- NRXP Strong Buy
- Analyst Count
- MYND 0
- NRXP 4
- Target Price
- MYND N/A
- NRXP $28.25
- AVG Volume (30 Days)
- MYND 11.2K
- NRXP 128.2K
- Earning Date
- MYND 04-29-2025
- NRXP 05-13-2025
- Dividend Yield
- MYND N/A
- NRXP N/A
- EPS Growth
- MYND N/A
- NRXP N/A
- EPS
- MYND N/A
- NRXP N/A
- Revenue
- MYND $267,380,999.00
- NRXP N/A
- Revenue This Year
- MYND N/A
- NRXP N/A
- Revenue Next Year
- MYND N/A
- NRXP N/A
- P/E Ratio
- MYND N/A
- NRXP N/A
- Revenue Growth
- MYND N/A
- NRXP N/A
- 52 Week Low
- MYND $0.61
- NRXP $1.10
- 52 Week High
- MYND $3.89
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- MYND 34.19
- NRXP 48.76
- Support Level
- MYND $0.63
- NRXP $1.85
- Resistance Level
- MYND $0.71
- NRXP $2.07
- Average True Range (ATR)
- MYND 0.08
- NRXP 0.15
- MACD
- MYND 0.01
- NRXP 0.03
- Stochastic Oscillator
- MYND 25.65
- NRXP 71.43
About MYND Mynd.ai Inc.
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.